-
Thematic Analysis
Cloud Computing – Thematic Intelligence
Cloud Computing Thematic Report Overview The cloud services sector competes to provide the best artificial intelligence (AI) platforms and services, partly catalyzed by the emergence of generative AI. AI is now central to the cloud services market, from developing custom chips and supporting workloads and providing the models and tools necessary to develop AI-enabled solutions. The Cloud Computing  thematic intelligence report provides an overview of the cloud computing theme. It identifies the key trends impacting the growth of the theme...
-
Product Insights
NewRetinitis Pigmentosa (Retinitis) – Drugs In Development, 2024
Empower your strategies with our Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2024 report and make more profitable business decisions. Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa (Retinitis) drugs in development market research report provide comprehensive information on...
-
Product Insights
NewMacular Edema – Drugs In Development, 2024
Empower your strategies with our Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the...
-
Product Insights
NewOpen-Angle Glaucoma – Drugs In Development, 2024
Empower your strategies with our Open-Angle Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure (IOP) that damages the optic nerve, leading to gradual and irreversible vision loss. It is the most common form of glaucoma and develops slowly over time, often without noticeable symptoms in the early stages. In open-angle glaucoma, the drainage system within the eye becomes less efficient over time, leading to...
-
Product Insights
NewRetinal Vascular Occlusion – Drugs In Development, 2024
Empower your strategies with our Retinal Vascular Occlusion – Drugs In Development, 2024 report and make more profitable business decisions. Retinal vascular occlusion is a condition that affects the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. It occurs when a blood vessel is blocked by a clot or compressed by another vessel, preventing blood from reaching or leaving the retina. This can cause vision loss or blindness in the affected eye. There...
-
Product Insights
NewRetinal Vein Occlusion – Drugs In Development, 2024
Empower your strategies with our Retinal Vein Occlusion – Drugs In Development, 2024 report and make more profitable business decisions. Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age. The Retinal Vein Occlusion drugs in...
-
Product Insights
NewNon-infectious Uveitis – Drugs In Development, 2024
Empower your strategies with our Non-infectious Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. Noninfectious uveitis can result from an eye injury or a disease somewhere else in your body. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve...
-
Product Insights
NewUveitis – Drugs In Development, 2024
Empower your strategies with our Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. The predisposing factors...